DAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTING

Malhan, S.Guler, S.Yetkin, I.Ignacio, T.J.Verheggen, B.Charokopou, M.2019-10-062019-10-0620151098-3015https://www.valueinhealthjournal.com/article/S1098-3015(15)04172-8/pdfhttp://hdl.handle.net/11727/4055enginfo:eu-repo/semantics/openAccessDAPAGLIFLOZIN VERSUS A DIPEPTIDYL PEPTIDASE 4 INHIBITOR (DPP4) BOTH ADDED TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM): IMPACT ON HEALTH, QUALITY OF LIFE AND COSTS IN THE TURKISH CLINICAL SETTINGconferenceObject187A607A607000209861300568